Hesham Shehata is a Principal Scientist at Genentech, specializing in Oncology Biomarker Development since 2022. They previously served as a Senior Research Scientist at Gilead Sciences, where they developed a therapeutic vaccine for HIV in 2021. With a PhD in Cellular and Molecular Immunology from Cincinnati Children's Hospital Medical Center, their dissertation research focused on novel mechanisms influencing NK cell activity during aging. Hesham also held postdoctoral and teaching roles, contributing significantly to the fields of immunology and oncology over the past decade.
This person is not in the org chart
This person is not in any teams
This person is not in any offices